Ophthalmic CDMO Services

Unique combination "ciprofloxacin 3 mg + Fluocinolone 0.25 mg" topical solution 

Indication: Acute otitis externa and acute otitis media with perforated eardrums in adults and pediatric patients. 
Dosage regimen: B.I.D x 7 days
Presentation of multi-dose 10 ml and unit dose vials (14...

Fluocinolone acetonide, topical solution. Ekzem is indicated for the treatment of otic eczema in adults. Demonstrated efficacy and safety in clinical studies 
Available in unit dose vials of 0.4 ml each. (30 vials x box)

Chlorhexidine digluconate 1% Cristalmina®, offers a quick action and long-lasting effect.
Cristalmina®, the antiseptic leader in the Spanish market, is the most complete, for the whole family 

Indication: Minor skin wounds and burns, even for the umbilical cord in newborns.

Ciprofloxacin 3 mg, topical solution. 

Indication: AOE 
Dosage:  B.I.D x 7 days.
Presentation: Available in multidose 10ml  and unit dose vials (15 vials).

SVT-15473 is the first strongest ophthalmic corticosteroid formulated in nanoemulsion (nanodroplets below ~30nm), using IMPACT-SVT®, a patented drug delivery technology, and in single-dose vials, using Blow-Fill-Seal technology packaging.

SVT-15473 has&nbs...

Clotic® is a broad-spectrum otic antimycotic agent effective against pathogenic dermatophytes, yeasts and several species of fungus, Well-recognized safety and efficacy.
The first and only treatment with clinical evidence against otomycosis. Preservative-free.

Indication: Otic fu...

Over 65 years of experience in developing & manufacturing pharmaceutical products for different markets. Operational Excellence, Flexibility & Adaptability.
Salvat offers integrated CDMO services. We have 3 manufacturing facilities in Barcelona, Madrid, and Miami with the capacity to ...

Salvat specialize in developing and manufacturing sterile liquid pharmaceutical products in single-dose vials, using Blow-Fill-Seal technology (BFS). 

Advantages of using Blow-Fill-Seal technology in your products: 
• Innovation in the format, giving differentiation to your produc...

Bimeox® Bimatoprost 0.3 mg/ml, a well-known prostaglandin analogue eye drop, preservative-free, presented in single-dose vials using our Blow-Fill-Seal Technology.

• Innovative format in single-dose vials • Preservative-free for better tolerability • Sterile until ope...

Tanolux® Latanoprost 50 ug/ml, a well-known prostaglandin analogue eye drop, presented in single-dose vials using our Blow-Fill-Seal Technology.

• Innovative format in single-dose vials • No cold chain required, easy to store & carry • Vey low solvents concentration vs ...

Tebarat 0.5 mg/ml eye drops are indicated for the treatment and prevention of allergic conjunctivitis. Treatment and prevention of seasonal allergic conjunctivitis symptoms in adults and children aged 4 years and over.Treatment of non-seasonal (perennial) allergic conjunctivitis symptoms in adults and chil...

Symptomatic relief of moderate to severe dry eye syndrome, using IMPACT-SVT® nanoemulsion patent drug delivery technology. 

Holistic approach for a multi-factorial pathology: anti-inflammatory, antioxidant, mucogenic, mucoadhesion, lubrication, and anti-evaporative activity. •...

Salvat Laboratories, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans. 

Cristalmina®, offers a quick action and long-lasting effect. 
Indicated in the disinfection of burns and superficial wounds; even for the umbilical cord in newborns.

Chlorhexidine is the antiseptic of reference, widely recommended in different clinical guidelines.

Licensing opportunity: Cristalmina®, 10 mg/ml, cutaneous spray solution in 25 ml & 125 ml.

• The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa.

• Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international level. 

 

Salvat offers an integrated End-to-Endsolution, to ensure your project’s commercial success. We offer the latest technologies withoptimum quality, flexibility andoperational excellence. With over 65years of experience, we can provide theservices and solutions that make ourpartners successful.

Salvat Laboratories, the international company, which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.

Sharing a commitmentto patients worldwide

LICENSING-OUT our products focuson Ophthalmology, Otorhinolaryngology,Gastroenterology & Consumer Health Care.


LICENSING-IN products for the Spanish,Portuguese, African and Central Americamarkets. Our areas of interest are in Rx productsat Ophthalmology, Otorhinolaryngology andGastroenterology.

Salvat has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug mucus penetration and bio-adhesion, providing excellent ocular comfort.

IMPACT-SVT® made it possible to develop SVT-15473, using the strongest corticosteroid in the global market.

Over 60 years of experience in the pharmaceutical industry Salvat offers a complete CDMO services 
Expertise in Blow-Fill-Seal technology 
Manufacturing sites located at Barcelona, Madrid & Miami